🧬 将两种抗体-药物偶联物与免疫疗法结合，能否为治疗初治的转移性尿路上皮癌提供新思路？
在 @myESMO #ESMO26 上，TROPHY-U-01 的中期结果揭示了 sacituzumab govitecan、enfortumab vedotin 和 zimberelimab 的潜力。@UChicago
阅读更多：https://www.onclive.com/view/sacituzumab-govitecan-triplet-elicits-durable-responses-in-treatment-naive-metastatic-urothelial-cancer #medtwitter #oncology
289 浏览 · 2 赞 · 1 转发 · 0 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org来源：OncLive.com · x.com